By Adriano Marchese
Regeneron Pharmaceuticals signed a new manufacturing-and-supply agreement with Fujifilm Diosynth Biotechnologies to double its large-scale manufacturing in the U.S.
Regeneron's new investment with Fujifilm, whose total value is estimated to exceed $3 billion, will expand the Tarrytown, N.Y., biotechnology company's manufacturing capabilities at Fujifilm's Holly Springs, N.C., campus, nearly doubling its large-scale capacity in the U.S.
This expansion will increase the production of bulk drug substances and Regeneron's commercial biologic medicines, the company said Tuesday.
Fujifilm Diosynth Biotechnologies, a subsidiary of Fujifilm, which develops manufacturing for biologics, vaccines and advanced therapies, will provide Regeneron with access to its new state-of-the-art biopharmaceutical facility over a 10-year period.
The investment comes at the same time as Regeneron's initiatives in New York State, including a roughly $3.6 billion expansion of its Tarrytown campus that will bolster research, preclinical manufacturing and support facilities.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
April 22, 2025 06:54 ET (10:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。